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Abstract 
Uniform gold nanostars (Au NS) were conjugated with cyclic RGD (cRGD) and near infrared 
(NIR) fluorescence probe (MPA) or anti-cancer drug (DOX) to obtain multi-functional nano-
constructs, Au-cRGD-MPA and Au-cRGD-DOX respectively. The NIR contrast agent 
Au-cRGD-MPA was shown to have low cytotoxicity. Using tumor cells and tumor bearing mice, 
these imaging nanoparticles demonstrated favorable tumor-targeting capability mediated by RGD 
peptide binding to its over-expressed receptor on the tumor cells. The multi-therapeutic analogue, 
Au-cRGD-DOX, integrates targeting tumor, chemotherapy and photo-thermotherapy into a 
single system. The synergistic effect of photo-thermal therapy and chemotherapy was demon-
strated in different tumor cell lines and in vivo using S180 tumor-bearing mouse models. The 
viability of MDA-MB-231 cells was only 40 % after incubation with Au-cRGD-DOX and irradiation 
with NIR light. Both tail vein and intratumoral injections showed Au-cRGD-DOX treated mice 
exhibiting the slowest tumor increase. These results indicate that the multifunctional nanocon-
struct is a promising combined therapeutic agent for tumor-targeting treatment, with the potential 
to enhance the anti-cancer treatment outcomes. 
Key words: gold nanostar, tumor-targeting, RGD receptor, near infrared imaging, photo-thermal 
therapy. 
Introduction 
Although enormous efforts have been expended 
into the development of effective methods for tumor 
therapy in the past decades, cancer remains one of the 
most difficult diseases to treat as well as a leading 
cause of morbidity and mortality. The limitations of 
the existing single-modality treatments such as 
chemotherapy, radiotherapy, immunotherapy, gene 
therapy and thermotherapy are well known, necessi-
tating the use of multi-modality treatments to im-
prove treatment outcomes in recent years [1, 2]. In 
contrast to the single treatment regimen, combination 
therapies such as chemotherapy and thermotherapy 
have been reported to synergistically improve the 








Gold nanoconstructs have been intensely inves-
tigated as the platform for multi-modality treatment, 
especially for the chemo-photothermal therapy be-
cause of two major features. First, the surface of gold 
nanomaterials can be easily functionalized with 
chemotherapeutics and other functional ligands 
through the reactive groups of the capping agents (eg. 
amino group, and carboxyl group) or through thi-
ol-mediated binding to gold surface. Second, when 
the tunable surface plasmon resonance (SPR) of gold 
nanoconstructs matches the wavelength of irradiating 
light, coherent oscillations of electrons in the conduc-
tion band will induce photothermal conversion by 
converting the absorbed light to heat [5]. More im-
portantly, unlike the visible light, light at 
near-infrared (NIR) light is poorly absorbed by en-
dogenous chromophores in tissues, including water, 
melanin and hemoglobin. This favors deep penetra-
tion of NIR light into tissue, thus excitation of the 
non-superficial target objects in the body [6]. 
A variety of gold nanoconstructs, such as gold 
naonrods [7, 8], nanoshells [9], nanocages [10], hollow 
nanospheres [11], and branched gold nanoparticles 
[12] have been proved to exhibit plasmon resonance 
in the NIR region, and produce hyperthermia upon 
the NIR laser irradiation. Huang et al. [13] proposed 
the concept of plasmon photothermal therapy (PPTT) 
using gold nanoparticles for localized photothermal 
therapy. Particularly, interest in the use of branched 
gold nanoparticles or gold nanostars (Au NS) with the 
plasmon peaks tunable in the infrared range has in-
creased because of the ease of synthesis for large scale 
production, high surface-to-volume ratio useful for 
improving drug loading efficiency, and surface 
plasmon resonance in the “NIR transparent window” 
for deep tissue imaging [14-17]. Yuan et al. [18] re-
ported that gold nanostars functionalized with 
TAT-peptides efficiently internalized in cells and 
demonstrated that these particles are promising 
agents for cancer therapy via photothermolysis.           
In order to increase the accumulation of nano-
particles in tumor sites and lower the side effects on 
normal tissues, many investigators have functional-
ized nanoparticles with ligands such as aptamer, 
peptide, and oligosaccharide for active tumor target-
ing. Among the various tumor-targeted ligands, argi-
nine-glycine-aspartic acid (RGD) peptide is one of the 
most effective and widely used compounds for de-
livery imaging agents and drugs to tumors [19]. The 
RGD receptor, integrin αvβ3, plays a critical role in 
regulating tumor growth and metastasis as well as 
tumor-mediated angiogenesis. It is over-expressed on 
the surface of a variety of tumor cells including hu-
man malignant melanoma, breast cancer, and ad-
vanced glioblastoma [20]. To improve the affinity 
between the ligands and αvβ3 receptor, diverse mul-
tivalent cyclic RGD-based peptides have been de-
signed. Choi et al. [21] demonstrated that a dye-RGD 
peptide conjugate provides high sig-
nal-to-background ratio when targeted to cancer cells. 
Similarly, Zhou et al. [22] also demonstrated 
99mTc-labeled cyclic RGD dimmer efficiently detect-
ed integrin αvβ3-positive tumors. 
In the present study, Au NS was prepared by 
reducing Au3+ in HEPES buffer using the “green” 
method reported by Xie et al. [23] Doxorubicin (DOX) 
and cyclic RGD (cRGD) peptide was covalently linked 
to the surface of Au NS via glutathione (GSH) to form 
Au-DOX, Au-cRGD, and Au-cRGD-DOX. We also 
labeled the cRGD-modified Au NS (Au-cRGD) with a 
hydrophilic indocyanine green (ICG) derivative 
(MPA) to investigate the biodistribution of Au NS and 
to assess the selective uptake of Au NS in tumors after 
attachment of cRGD. The affinity of Au-cRGD-DOX 
for different tumor cells was examined by fluores-
cence microscopy and the selective tumor-uptake of 
Au-cRGD-MPA was verified by monitoring its in vivo 
dynamics in real time. Furthermore, we also com-
pared the chemo-photothermal therapeutic efficacy of 
Au-cRGD-DOX with free DOX, Au NS, and Au-DOX 
in cells and tumor-bearing mice by irradiation with 
NIR laser. Finally, we investigated the influence of 
administrative routes on anti-tumor effect of 
Au-cRGD-DOX by injecting DOX, Au NS, Au-DOX, 
Au-cRGD-DOX intratumorally and intravenously.  
Materials and Methods 
Materials  
4-(2-hydroxyethyl)-1-piperazineethane-sulfonic 
acid (HEPES) was obtained from Sigma Aldrich 
(Tianjing, China). HAuCl4 was purchased from 
Guoyao Reagent Corporation (Shanghai, China) and 
used as received. Reduced glutathione (GSH) was 
obtained from Sangon Biotech Co., LTD (Shanghai, 
China) and cyclic RGD peptide (cyclo 
(Arg-Gly-Asp-DTyr-Lys)) was purchased from GL 
Biochem Co., Ltd (Shanghai, China). MPA (MW: 995) 
was prepared in our laboratory. Doxorubicin (DOX, 
MW: 149.15), 1-ethyl-3-[3-diMethylaminopropyl] 
carbodiimide hydrochloride (EDC), N, 
N’-Dicyclohexylcarbodiimide (DCC), 
N-hydroxysuccinimide (NHS), 3-(4, 5- diMethylthi-
alzol-2-yl)-2, 5-diphe-nyltetrazolium bromide (MTT), 
RPMI 1640, fetal bovine serum (FBS), penicillin, 
streptomycin, and trypsin-EDTA were purchased 
from commercial sources. Ultrapure millipore water 
(18.2 MU) was used. All other solvents and reagents 




used in this study were certified analytical reagent 
grade. 
Preparation of Au NS and its conjugates 
Synthesis of Au NS and Au-Glutathione (Au-GSH) 
  All the glassware should be washed by Aqua 
Regia and rinsed by ultrapure water repeatedly. In a 
typical experiment, aqueous HAuCl4 solution (10 μL, 
40 mM) was added to HEPES solution (2.0 mL, 140 
mM, pH=7.4±0.1) at 25 °C, and the reaction solution 
was degassed by N2 purging for 10 min. Without 
shaking, Au NS formed in 1 hour, and the color of the 
solution changed from colorless to dark green. GSH 
(5.0 mg) was added to the solution after the synthesis 
finished and the mixture was left overnight to form 
the nanoconstruct (Au-GSH). After 12 h, the solution 
was centrifuged at 8000 rpm for 15 min. The super-
natant was discarded, and ultrapure water (1.0 ml) 
was added to re-dissolve the precipitate. 
Synthesis of Au-cRGD, Au-DOX and 
Au-cRGD-Doxorubicin (Au-cRGD-DOX) 
  Cyclic RGD peptide was immobilized onto 
Au-GSH by using coupling agents (EDC and NHS) 
[24]. Briefly, EDC (5.0 mg) and NHS (4.6 mg) were 
added into Au-GSH solution (5.0 ml) prepared above 
and the mixture was stirred at room temperature for 4 
h. After the reaction, cRGD (3.1 mg) and DOX (5.4 mg) 
were added to the activated Au-GSH solution simul-
taneously and the new mixture was incubated over-
night. Subsequently, the solution was centrifuged at 
8000 rpm for 15 min. The residual small molecules 
including EDC, NHS and RGD in the supernatant 
were discarded. 2.0 mL ultrapure water was utilized 
to dissolve the precipitate. Au-cRGD and Au-DOX 
were synthesized according to the above method ex-
cept DOX or cRGD was not included in the reaction.  
Synthesis of Au-cRGD-MPA conjugates 
MPA (1.0 mg) was activated with DCC and NHS 
(molar ratio of MPA: DCC: NHS is 1: 1.2: 1.5) at room 
temperature in the dark for 3 h. The above activated 
MPA (200 µL) was then uniformly mixed with puri-
fied Au-cRGD (1.0 mL) and incubated at room tem-
perature with stirring in the dark for 12 h. The incu-
bation product was purified by centrifugation at 8000 
rpm for 15 min to remove the small molecules in the 
supernatant. Ultrapure water (0.5 mL) was used to 
re-dissolve the precipitate.  
Characterization 
Morphology and Size Distribution  
The size and morphology of Au NS and 
Au-cRGD-DOX were measured by JEOL JEM-2100 
and transmission electron microscope (TEM). A dilute 
solution of the sample was added dropwise into 
400-mesh carbon-coated copper grids and the exces-
sive solvent was immediately evaporated before mi-
croscopy. The hydrodynamic size and polydispersity 
of Au NS and Au-cRGD-DOX were measured by 
Mastersizer 2000 Laser Particle Size Analyzer (Mal-
vern, British) at 25 °C. A helium-neon laser (10 mW 
max, Wand wavelength of 633 nm) was used as the 
light source. Polydispersity values were utilized to 
evaluate the distribution of the nanoparticles popula-
tion. 
Optical Properties of Au NS and its Conjugates 
The absorption spectra of Au NS, MPA, 
Au-MPA, Au-cRGD-MPA, DOX, Au-DOX and 
Au-cRGD-DOX were acquired with Lambda 25 
UV-Vis spectrophotometer (Perkin Elmer, US). The 
corresponding fluorescence spectra of the materials 
were measured at room temperature using a S2000 
eight-channel optical fiber spectrofluorometer 
equipped with a Xenon lamp.  
Photo-thermal effect of the nano-conjugates of Au NS 
in solutions 
Change in temperature as a function of time was 
used to determine the photothermal effect of the na-
noparticles. The DMEM medium with PBS, Au-MPA, 
Au-cRGD-MPA, Au-DOX and Au-cRGD-DOX (50 
µg/mL) were each added into different wells of the 
96-well plate.The temperature increase was recorded 
after exposing the samples to a 765 nm laser (Shang-
hai nLight Optics Company) at different light irradia-
tion time (0 min, 1 min, 5 min). The beam diameter 
was 1 cm and the power density of laser source was 
fixed at 1.0 W/cm2.  
Drug loading efficiency and in vitro drug release profile 
  To calculate the DOX loading efficiency, 
Au-cRGD-DOX was collected by centrifugation and 
the unconjugated DOX in the supernatant was quan-
tified by using DOX UV calibration curve at 481 nm. 
The DOX loading was calculated according to the 
formula: drug loading (DL) = (mass of drug conju-
gated with Au NS / total mass of drug conjugated 
and Au NS).  
  To investigate the in vitro DOX release profile, 
PBS containing 10 % fetal bovine serum with or 
without GSH (10 mM) were used to dissolve 
Au-cRGD-DOX in a dialysis bag. Dislysate (2 mL) was 
withdrawn at different time intervals (0.5 h, 1 h, 2 h, 6 
h, 10 h, 16 h, 20 h and 24 h) and an equal volume of 
PBS was added to the solution outside of the dialysis 




bag to maintain the net volume of the system. The 
absorbance peak (481 nm) of the solutions were de-
tected and the quantities of the free dugs were calcu-
lated from the standard curve defined by the equation 
y = 0.3246x - 0.0042 (R2 = 0.9996). 
Cell studies 
Cell culture 
The human cell lines, MDA-MB-231 (breast can-
cer), Bel-7402 (liver cancer) and MCF-7 (breast cancer) 
used in this study, were all purchased from American 
Type Culture Collection (ATCC, USA). The cell lines 
were cultured in RPMI-1640 medium supplemented 
with 10% (v/v) calf serum, penicillin (100 U ml-1), and 
streptomycin (100 mg ml-1). The cells were maintained 
at 37 °C in a humidified atmosphere containing 5% 
CO2. 
Assessment of cell uptake 
The targeting ability of DOX, Au-DOX and 
Au-cRGD-DOX were evaluated using the three tumor 
cells lines, MDA-MB-231, Bel7402, and MCF-7 cells. 
The cells were seeded in laser confocal fluorescence 
microscope (LCFM) culture dishes with a density of 
4×105 cells/well and subsequently incubated at 37 °C 
in a humidified atmosphere containing 5% CO2. When 
the whole cells reached 70 % ~ 80 % confluence, 20 µL 
of DOX, Au-DOX and Au-cRGD-DOX were added 
into different dishes and then incubated for 1 h. In 
addition, MDA-MB-231 cells were treated with 
Au-cRGD-DOX for 8 h, followed by incubation with 
Hoechst 33342 solutions (100 µL, 10 µg/mL) for 30 
min. The information was used to determine the basis 
for understanding the intracellular kinetics of 
Au-cRGD-DOX. Subsequently, the cells were washed 
three times with Dulbecco’s phosphate buffered saline 
(PBS, pH 7.0) before examining the probe’s affinity for 
cancer cells by LCFM (FV1000, Olympus, Japan). The 
red fluorescence of DOX was captured under 488 nm 
light excitation. Intracellular uptake of the different 
probes was determined from the red fluorescence 
intensity in the region of interest (ROI) by using Scion 
Image software. 
Cell apoptosis evaluation 
To evaluate the therapeutic efficacy of Au NS, 
DOX, Au NS (NIR light), Au-DOX (NIR light) and 
Au-cRGD-DOX (NIR light), the induction of apoptosis 
in MDA-MB-231 cells was studied by determining the 
cell number and cell morphology. Specifically, cells 
were plated at a density of 4×105 cells/dish in confo-
cal specific dish and subsequently incubated under 
the culture condition for 36 h. The cells were treated 
with 100 µL solutions of Au NS, DOX (5.0 µg/mL), 
Au-DOX and Au-cRGD-DOX (conjugated DOX: 5.0 
µg/mL) for 4 h. The photothermal treatment was 
monitored using a 765 nm high power multimode 
pump laser (Ennai, Shanghai, China). The beam di-
ameter was 2.0 cm and the power density of laser 
source was fixed at 1.0 W/cm2. The cells were ex-
posed under the 765 nm laser for 10 min and then 
washed three times with PBS (pH = 7.0). The residual 
cells and the morphological changes were displayed 
by the differential interference contrast (DIC) mode of 
LCFM. For MDA-MB-231 and MCF-7 cells, the in-
duced cell apoptosis was also characterized by cell 
membrane and cell nucleus staining. Annexin V-FITC 
(5 µL) and propidium iodide (5 µL) were added into 
the culture dish and incubated at room temperature in 
the dark for 10 min. After adding 500 µL of binding 
buffer, the cells were directly visualized by LCFM (40 
× objective magnification). The red and green fluo-
rescence intensity was identified from the ROI of each 
image by Scion Image software. 
To quantitatively evaluate the effect of the na-
nomaterials on MDA-MB-231 cells, MTT assay was 
also carried on Au NS, DOX, Au-DOX and 
Au-cRGD-DOX using a concentration range of 0.7 
µg/mL to 446.4 µg/mL for Au NS and its conjugates 
and 0.02 µg/mL to 12.5 µg/mL for free DOX and 
conjugated DOX. After the cells were incubated for 4 
h, the photothermal treatment was then performed 
using a 765 nm laser. The beam diameter was 2.0 cm 
and the power density of laser source was fixed at 1.0 
W/cm2. The cells were exposed under the 765 nm 
laser for 15 min, and then incubated for another 12 h. 
Each well was replaced and the cells were washed 
three times with PBS (pH 7.0) before addition of 20 µL 
of MTT solution (5.0 µg/mL). After incubating an-
other 4 h, the medium containing MTT was carefully 
removed from each well and DMSO (150 µL) was 
added to each well to dissolve the purple crystals. The 
plates were gently shaken for 10 min at room tem-
perature before measuring the absorbance at 580 nm. 
All test samples were assayed in quadruplicate and 
the cell viability was calculated using the following 
formula: Cell viability = (Mean absorbance of test 
wells - Mean absorbance of medium control wells) / 
(Mean absorbance of untreated wells - Mean absorb-
ance of medium control well) ×100%. 
Animal experiments 
Animal subjects and tumor model 
Athymic nude mice and normal (Kunming) mice 
were purchased from Charles River Laboratories 
(Shanghai, China) for in vivo investigation. All animal 
experiments were carried out in compliance with the 




Animal Management Rules of the Ministry of Health 
of the People’s Republic of China (Document NO. 55, 
2001) and the guidelines for the Care and Use of La-
boratory Animals of China Pharmaceutical Universi-
ty. 
Dynamic distribution of Au-cRGD-MPA in tumor 
bearing mice 
To investigate the targeting ability of the probes, 
two types of tumor models were established by sub-
cutaneous injection of MDA-MB-231 (high αvβ3 re-
ceptor expression) and MCF-7 (low αvβ3 receptor ex-
pression) tumor cells (~ 5 × 106 in 80 µL of PBS) into 
the axillary fossa of female athymic nude mice (n = 5 
for each model).   
As the tumors grew to a diameter of up to 0.5 cm, 
Au-cRGD-MPA (0.2 mL, 10 mg/kg) was injected into 
MDA-MB-231 and MCF-7 tumor-bearing mice 
through the vena caudalis. The nude mice were then 
immobilized on a Lucite jig. NIR imaging system 
equipped with a 765 nm laser as excitation source was 
employed to trace the distribution of the probe. The 
background image of the mice was taken prior to the 
injection. A series of images were collected at 5 min, 1 
h, 2 h, 4 h, 12 h, 24 h and 48 h post-injection respec-
tively. To further compare the targeting ability of the 
probe for MDA-MB-231 and MCF-7 tumors, tumor to 
normal tissue contrast ratios (T/N) at different time 
points were calculated by using ROI functions of 
Scion Image software. In each case, the background 
fluorescence that was measured before injection of the 
conjugates was subtracted from the post injection 
fluorescence. 
  In order to confirm the bio-distribution of the 
Au-cRGD-MPA in living mice, some major organs 
(heart, liver, spleen, lung, kidney, intestine and tumor 
of the subject MDA-MB-231 tumor-bearing mice were 
excised at 48 post-injection and detected by NIR flu-
orescence imaging system. 
Therapeutic efficacy evaluation of Au-cRGD-DOX 
S180 tumor model for therapy evaluation was 
established by subcutaneously inoculating S180 cells 
(~8×106) into the nether axillary fossa in the mice (n = 
60). The mice were investigated after 7 days of inocu-
lating. 
When the tumor was fully developed, the mice 
were randomly divided into six groups (n = 10) for 
each group. We intratumoral injected 50 μL of Saline, 
1.4 mg/kg DOX, 50 mg/kg Au NS, 50 mg/kg Au-DOX 
(containing 3.2 mg/kg DOX) or 50 mg/kg 
Au-cRGD-DOX (containing 1.4 mg/kg DOX) into the 
mice and Au-cRGD-DOX was also intravenously ad-
ministered in the mice (50 μL, 75 mg/kg). Groups 3, 4, 5 
and 6 were exposed to 1.0 W/cm2 NIR light for 10 min 
at 8 h after intravenous injection of the nanoparticles. 
Subsequently, each mouse underwent 4 intratumoral 
injection or tail vein injections once every other day. 
The tumor volume and body weight of each mouse 
were monitored every three days for 26 days. The 
tumor volume was calculated as length× (width) 2 
×1/2 with a caliper. The survival rate of the treated 
mice was calculated according to the equation: Sur-
vival rate = Ns/Nt × 100%, where Ns and Nt repre-
sent the number of surviving mice and the number of 
total mice in each group, respectively. 
To monitor the photothermal effect of laser ex-
posure, intratumoral injection of PBS, Au NS, 
Au-DOX and Au-cRGD-DOX (50 μg/mL) separately 
into S180 tumor-bearing mice was followed by irra-
diation with a 765 nm laser (beam diameter: 1 cm, 
powder density: 1.0 W/cm2.) for 10 min. A needle 
temperature probe (NR81530, TES, Shenzhen Yu-
anhengtong technology company) was used to detect 
the intratumoral temperature of different groups after 
laser treatment. 
Ex vivo Histopathology 
To further investigate the therapeutic effects of 
Au-cRGD-DOX on S180 tumor-bearing mice treated 
by tail vein or intratumoral injection, the tumors were 
excised for histopathologic analysis on day 16 
post-injection. The tissue was fixed with 10% neutral 
buffered formalin and embedded in paraffin. The 
sliced tumors (8 mm) were stained with Hematoxylin 
and Eosin (H&E) and observed by a BX41 bright field 
microscopy (Olympus). 
Statically Analysis  
Significant differences were determined using 
the Student’s t-test where differences were considered 
significant (p < 0.05). All data are expressed as mean ± 
standard error of the mean. 
Result and Discussion 
Preparation and characterization of Au NS 
and its nanoconjugates 
  Bio-compatible Au NS was prepared by re-
ducing HAuCl4 with HEPES, a popular pH buffer 
used extensively in tissue culturing [18, 25]. The pro-
cess of functionalization is illustrated in Figure S1 
(Supplementary Material). The morphology, size, and 
polydispersity index of Au NS and Au-cRGD-DOX 
were measured by TEM and Laser Particle Size Ana-
lyzer. TEM analysis showed average size of 25 nm 
and 80 nm for Au NS and Au-cRGD-DOX, respec-
tively (Fig. 1A and Fig. 1B). The hydrodynamic di-




ameters of Au NS and Au-cRGD-DOX were 32.6 nm 
(polydispersity index: 0.216) and 58.4 nm (polydis-
persity index: 0.232), respectively (Fig. 1C and Fig. 
1D). It was clear that upon the nanostars functionali-
zation with cRGD and DOX, the nanostars aggregated 
into larger uniform clusters. In addition, the DOX 
loading rate was 2.8 % (w/w) by quantifying the un-
conjugated DOX in the supernatant. 
The modification of Au NS by DOX, RGD and 
MPA was monitored by UV-Vis absorption spectra 
and fluorescence spectra (Fig. 2). Consistent with the 
previous reports [18, 26], Au NS showed distinct ab-
sorption peak at 740 nm (Fig. 2A and Fig. 2C). The 
absorption peak at 350 nm could be attributed to the 
molecules on the surface of Au NS. The conjugates, 
Au-MPA and Au-cRGD-MPA, still exhibited the 
characteristic absorption peaks of MPA (780 nm). 
However, the characteristic absorption peak of Au NS 
became indistinct after conjugation with MPA, cRGD 
or DOX, which was in agreement with the TEM and 
DLS results. Although the absorption spectrum of Au 
NS (650-780 nm) and the emission spectrum of MPA 
(750-810 nm) partly overlapped each other in NIR 
region, the fluorescence of MPA was maintained after 
conjugation with Au NS, facilitating the use of 
Au-cRGD-MPA for in vivo imaging (Fig. 2A and Fig. 
2B). The DOX loading of 2.8 % (w/w) was determined 
by quantifying the unconjugated DOX in the super-
natant. Additionally, Fig. 2D suggests that the fluo-
rescence peak emitted by DOX did not shift after 
conjugation with Au NS. To further investigate the 
stability of the nanoparticles, the UV-Vis spectra of 
Au NS and Au-cRGD-DOX in fetal bovine serum 
immediately and after 8 h incubation were measured 
(Fig. 2E). The result indicates that there was no obvi-
ous change in the absorption spectra. The in vitro 
DOX release profile is shown in Fig. 2F. Obviously, 
DOX release was much faster in PBS containing 10 % 
fetal bovine serum and GSH (10 mM) than in the in-
cubation system without GSH. Almost 80% of DOX 
was released from Au-cRGD-DOX in the initial 10 h 
when incubated with GSH, and a complete release 
was achieved at 24 h incubation. In contrast, only 30 % 
of the drug was released in the solution without GSH.  
 
 
Fig 1. TEM images of Au Ns A) before (as-synthesized) and B) after conjugation with cRGD and DOX; Hydrodynamic diameter of Au Ns C) before (as-synthesized) 
and D) after conjugation with cRGD and DOX measured by laser particle size analyzer. 
 





Fig 2. A) Absorption spectra of Au NS, MPA, Au-MPA and Au-cRGD-MPA; B) Fluorescence spectra of MPA, Au-MPA, Au-cRGD-MPA and florescence image of 
Au-cRGD-MPA collected by NIR fluorescence imaging system; C) Absorption  spectra of Au NS, DOX, Au-DOX, Au-cRGD-DOX; D) Fluorescence spectra of 
DOX, Au-DOX,  Au-cRGD-DOX; E) UV-Vis spectra of Au NS and Au-cRGD-DOX dispersed in fetal bovine serum immediately and after 8 h; F) The in vitro DOX 
release profile in PBS containing 10 % fetal bovine serum with or without GSH (10 mM). 
 
The results further demonstrate that the medium 
containing of the nanostructures (Au-MPA, 
Au-cRGD-MPA, Au-DOX and Au-cRGD-DOX) gen-
erated significant temperature increases upon excita-
tion (Fig. 3A). For example, Au-cRGD-MPA and 
Au-cRGD-DOX attained a temperature of 38.7°C and 
43.9°C in only 1 min and 5 min, respectively. Similar-
ly, the result from the in vivo photo-thermal evalua-
tion was consistent with the in vitro data (Fig. 3B). All 
the intratumoral temperature exceeded 43 °C for S180 
tumor-bearing mice treated with Au Ns, Au-DOX and 
Au-cRGD-DOX and irradiated by NIR light for 10 
min. On the contrary, no apparent temperature 
change was detected for PBS both in vitro and in vivo 
because of the low light absorption by the solution. 
The GSH coated Au NS have both carboxyl and 
amine groups on the surface. Alhough slower cen-
trifugation of 8000 rpm for 15 min instead of 12000 
rpm for 20 min was utilized to purify Au NS, the 
slight nanostars aggregation still persisted (Fig. 1C). 
This may be attributed to the cross linking induced by 
the coupling agents (EDC/NHS). The quenching ef-
fect of gold nanoparticles towards quantum dots and 
dye molecules had been widely reported [27-29]. 
However, our results demonstrated that the limited 
extent of overlap between absorption spectrum of Au 
NS and emission spectrum of MPA or DOX caused 
minimal quenching effect of Au NS. Simultaneously, 
the linkers with long chains could be anchored on the 
surfaces of Au NS, which may perturb the energy 
transfer by increasing the distance between Au NS 
and the attached molecule. In addition, quenching 
efficiency decreases with increasing nanoparticle di-
ameter, which favors the relatively larger size of Au 
NS [30-32].  




Cell targeting capability of Au-cRGD-DOX 
To visualize the cellular uptake of DOX, 
Au-DOX and Au-cRGD-DOX, the red fluorescence 
emitted by DOX was captured by LCFM (Fig. 4A) 
after free DOX and the nanoconjugates were incu-
bated with MDA-MB-231 and Bel-7402 tumor cells, 
which over-express integrin αvβ3, and MCF-7 tumor 
cells, which have low expression of integrin αvβ3. The 
weak red fluorescence of DOX in MCF-7 cells indi-
cates that low amount of DOX, Au-DOX or 
Au-cRGD-DOX had entered tumor cells. Similarly, 
the amount of DOX or Au-DOX that entered the 
MDA-MB-231 cells and Bel-7402 cells was so low that 
there was no significant difference between the fluo-
rescence intensity from these groups of cells and 
MCF-7 cells treated with DOX, Au-DOX, or 
Au-cRGD-DOX. By contrast, Au-cRGD-DOX in 
MDA-MB-231 and Bel-7402 tumor cells showed ob-
vious red fluorescence. The fluorescence intensity of 
the three cell lines incubated with different samples 
was compared (Fig. 4B). Significant differences ap-
peared in MDA-MB-231 and Bel-7402 cells. Addition-
ally, taking advantage of the "optical sectioning" 
function of LCFM, fluorescence images of 
MDA-MB-231 cells treated with Au-cRGD-DOX was 
reconstructed in three-dimensions (Fig. 4C). Obvi-
ously, Au-cRGD-DOX entered the cells, as evidenced 
by fluorescence signals appeared along the Z axis. All 
the results indicated clearly that the presence of cRGD 
on the surface of Au NS increased its cellular uptake 
by MDA-MB-231 and Bel-7402 cells. This result agrees 
with the work of Lee et al, [33] who demonstrated the 
targeted cellular uptake of cyclic RGD conjugated 
prodrugs via RGD-dependent endocytosis mecha-
nisms. 
 
Fig 3. A) Temperature of PBS, Au-MPA, Au-cRGD-MPA, Au-DOX and Au-cRGD-DOX (50 µg/mL) in DMEM medium versus exposure time under 1.0 W/cm2 NIR 
light irradiation; B) The intratumoral temperature of S180 tumor-bearing mice after intratumoral injection of PBS, Au NS, Au-DOX and Au-cRGD-DOX upon light 
irradiation for 10 min. 
 
Fig 4. The tumor-targeting efficacy of DOX, Au-DOX and Au-cRGD-DOX in different cell lines. A) Intracellular uptake of DOX, Au-DOX, Au-cRGD-DOX 
MDA-MB-231 cells, Bel-7402 cells and MCF-7 cells respectively after incubation for 1 h; Scale bar = 20 μm (objective: 20 ×; zoom: 4 × magnification). B) Mean red 
fluorescence intensity of different samples (DOX, Au-DOX, Au-cRGD-DOX) determined in MDA-MB-231 cells, Bel-7402 cells and MCF-7 cells; C) The recon-
structed three-dimensional fluorescence image of MDA-MB-231 cells treated with Au-cRGD-DOX for 1 h. (p < 0.05). 




To further understand the intracellular kinetics 
of the multifunctional nanoparticles, the fluorescence 
images of Au-cRGD-DOX after incubating with 
MDA-MB-231 cells for a longer time (8 h) were also 
collected and Hoechst was used for nucleus staining 
(Fig. 5). The result clearly indicated that 
Au-cRGD-DOX or released DOX entered the nucleus, 
with only a small fraction remaining in the cytoplasm 
after 8 h incubation (Fig. 5B). The fluorescence images 
at different slices (Fig. 5A) and the three dimensional 
fluorescence image re-constructed from the slice im-
ages (Fig. 5C) further confirmed that Au-cRGD-DOX 
or released DOX reached the nucleus. Dam et al. [34] 
designed a nanostructure composed of nucleo-
lin-specific aptamer and gold nanostars, which were 
actively transported to the nucleus after 5 h incuba-
tion, increasing significantly after 7 h, and induced 
major changes to the nuclear phenotype. In another 
study by Yuan et al. [18] TAT-peptide functionalized 
gold nanostars were observed in the nuclear region by 
two-photon photoluminescence imaging. However, 
they did not find any true intranuclear TAT-NS, ex-
cept some particles in the nuclear cleft. These results 
suggest that the red fluorescence observed from the 
nucleus in our study may be contributed by free DOX 
released from Au-cRGD-DOX as a result of the re-




Fig 5. A) The fluorescence images of Au-cRGD-DOX after incubating with MDA-MB-231 cells for 8 h at different optical slices (from 1417.60 µm to 1433.60 µm); 
B) Accumulation of Au-cRGD-DOX in the nucleus, indicated by the red fluorescence, was obviously observed from partial enlargement of the red fluorescence image 
at Z = 1424.00 µm; C) 3D fluorescence image of Au-cRGD-DOX reconstructed from Fig. 5A suggested that Au-cRGD-DOX were internalized by MDA-MB-231 cells 
and are transported to the nuclei.  
 
 





Fig 6. The biodistribution of Au-cRGD-MPA in different tumor-bearing mice models. In vivo fluorescence images of Au-cRGD-MPA in A) MDA-MB-231 (positive 
αvβ3 receptor expression) and B) MCF-7 (negative αvβ3 receptor expression) tumor-bearing mice model at different time intervals (5 min, 1 h, 2 h, 4 h, 12 h, 24 h and 
48 h); C) The ex vivo fluorescence images of isolated organs (heart, liver, spleen, lung, kidney, intestine and tumor) from the MDA-MB-231 tumor-bearing mice at 48 
h post-injection; the ex vivo fluorescence image of Au-cRGD-MPA in major organs (heart, liver, spleen, lung, kidney, intestine and tumor) detected at 48 h 
post-injection (MDA-MB-231 tumor-bearing mouse). D) Tumor-to-normal tissue (T/N) ratios of Au-cRGD-DOX in MDA-MB-231 and MCF-7 tumor-bearing mice 
at different post-injection time. (p < 0.05). 
 
Targeting ability of Au-cRGD-MPA in tumor 
bearing mice 
An important concern for nanoparticle-based 
treatments is whether the injected nanoparticles could 
preferentially accumulate in foci or can be cleared 
from the body. To trace the biodistribution and tumor 
targeting ability of the Au-cRGD, NIR fluorescence 
probe (MPA) was linked to the nanoconstruct for in 
vivo NIR imaging.  Mice bearing MDA-MB-231 (in-
tegrin αvβ3 positive) tumors and MCF-7 tumors (low 
integrin αvβ3 expression) were selected for the animal 
models. Series of in vivo NIR fluorescence images at 
different time intervals show that Au-cRGD-MPA 
initially distributed all over the body, and subse-
quently cleared by the hepatobiliary and renal path-
ways in MDA-MB-231 tumor-bearing mice (Fig. 6A). 
The fluorescence signal in MDA-MB-231 tumor was 
distinguishable from the normal tissues at 1 h 
post-injection, reaching peak intensity at 12 h 
post-injection before gradually disappearing within 
48. In contrast, MCF-7 tumor uptake in mice treated 
with Au-cRGD-MPA became visible after 2 h 
post-injection and rapidly disappeared from 4 h 
post-injection, which represented the contribution of 
enhanced permeation and retention in the tumor by 
the nanoconstructs (Fig. 6B). The ex vivo fluorescence 
images of the excised organs separated from 
MDA-MB-231 tumor-bearing mice confirmed that the 
nanoconstructs prominently accumulated in tumor 
and reticuloendothelial system of the liver even after 
the long circulation (Fig. 6C). To semi-quantitatively 
analyze the targeting efficacy of the probes for dif-
ferent tumors, fluorescence intensity of the tumors 
and normal tissues was analyzed at different time 
intervals (Fig. 6D). The fluorescence intensity ratio 
between MDA-MB-231 tumor and normal tissue 
(T/N) was 3.7 at 1 h post-injection of the probe, 
reaching a peak of 8.4 at 12 h post-injection, and de-
creasing to 1.1 at 48 h. For MCF-7 tumor-bearing mice, 
T/N was 2.6 at 1 h post-injection, reaching a peak of 
3.7 at 2 h post-injection, and rapidly declining to 1.4 at 
12 h. 
Although several research groups have investi-
gated the intracellular behavior of the gold nanostars 
by different techniques including multi-photon mi-
croscopy [35], confocal fluorescence microscopy [34], 
and high resolution TEM [18], the biodistribution of 
the gold nanostars in living subjects was still un-
known. In this work, NIR fluorescence imaging, pos-




sessing the advantages of effective, low-cost, 
non-invasive and flexible features, was utilized to in 
vivo evaluate the tumor-targeting capability of 
Au-RGD. A derivative of FDA approved NIR fluo-
rescence probe (MPA), which was provided with 
carboxyl group, was selected to conjugate with Au 
NS. The in vivo fluorescence imaging results indicat-
ed the high affinity and specificity of cRGD to integrin 
αvβ3 in MDA-MB-231 mouse model, which was con-
sistent with the tumor-targeting evaluation of 
Au-RGD in cells. Given the in vivo fluorescence im-
aging results, Au-RGD could serve as the drug carrier 
or therapy agents by selectively accumulating in high 
αvβ3 expression tumors in biological system. In addi-
tion, the renal clearance observed by in vivo (Fig. 6A) 
and in vitro (Fig. 6C)  imaging suggests that some of 
the dyes (MPA) were detached from Au NS surface in 
the blood circulation. Replacement of GSH in vitro or 
in vivo by other thiol-containing biomolecules will 
affect the imaging and therapy results. This poten-
tially deleterious effect could be avoided in future by 
using more stable thiol-containing molecules to bind 
with Au NS. 
Anti-tumor efficiency of Au-cRGD-DOX 
Therapeutic effects of Au-cRGD-DOX at cell level 
  To confirm the enhancement of anti-tumor ef-
ficacy of Au-cRGD-DOX, cytotoxicity effects of Au 
NS, free DOX, the photothermal effect of Au NS un-
der 765 nm laser irradiation for 10 min, and the com-
bined chemo- and photothermal effects of Au-DOX 
and Au-cRGD-DOX under 765 nm laser irradiation 
for 10 min were compared by evaluating the number 
and morphological changes of MDA-MB-231, 
Bel-7402, and MCF-7 tumor cells at 4 h after incuba-
tion with the five different samples. As shown in Fig. 
7A, different groups of cells showed diverse degrees 
of apoptosis. For the groups incubated with Au NS 
alone, the majority of the cells maintained their orig-
inal morphology. Compared to the group of cells in-
cubated with DOX or Au NS with laser irradiation, 
more obvious cellular morphological changing (be-
came rounded) characteristic of apoptosis could be 
observed among MCF-7, MDA-MB-231 and Bel-7402 
tumor cells, which have been incubated with  
Au-DOX or Au-cRGD-DOX and exposed to laser ir-
radiation. Furthermore, there was no obvious differ-
ence between the two groups of MCF-7 cells treated 
with Au-DOX and Au-cRGD-DOX. In comparison 
with the groups treated with Au-DOX, it is evident 
that much less MDA-MB-231 cells and Bel-7402 cells 
were left in dishes after the chemophotothermal 
treatment of Au-cRGD-DOX, which indicated en-
hanced anti-tumor efficacy of Au-cRGD-DOX to-
wards tumor cells with high expression of integrin 
αvβ3. Additionally, in vitro anti-tumor efficacy of 
Au-cRGD-DOX was also demonstrated by quantita-
tively evaluating its cytotoxicity effect via MTT assay 
on MDA-MB-231 tumor cells (Fig. 7B). All the samples 
showed dose-dependent anti-tumor activity. At the 
highest dose level, the inhibition ratio of 
Au-cRGD-DOX was over 90 % of total cells, which 
was much higher than that of Au NS (68 %), DOX 
(55%) and Au-DOX (80 %) at the same dose level.  
With the increase of the concentration of 
Au-cRGD-DOX, the cell viability distinctively de-
creased after incubation for 4 h, which correlated with 
Annexin V-FITC and PI staining (Fig. 8A and Fig. 8B). 
It was easy to distinguish non-apoptotic cells (no flu-
orescence), early apoptotic cells (green fluorescence), 
late apoptotic cells (green and red fluorescence) and 
necrotic cells (red fluorescence) [36]. When 
MDA-MB-231 cells were incubated with 
Au-cRGD-DOX, red fluorescence in nucleus appeared 
after 10 min exposure, which suggests the destruction 
of the cell membrane integrity and enzymes used in 
DNA synthesis. Nevertheless, only green fluorescence 
and less red dots were detected for other groups, 
which demonstrated that MCF-7 cells and 
MDA-MB-231 cells treated with Au NS, DOX and 
Au-DOX were in the early apoptotic period. The 
green fluorescence intensity and red fluorescence in-
tensity at different groups were also compared (Fig. 
8C and Fig. 8D). Obviously, Au-cRGD-DOX incubat-
ed MDA-MB-231 cells possessed the strongest red 
fluorescence after NIR light excitation. However, 
green fluorescence intensity in other groups far ex-
ceeded the red fluorescence intensity. These results 
illustrate that the tumor cells with positive expression 
of integrin αvβ3 have distinctly superior therapeutic 
efficacy than those cells with low expression of RGD 
receptors. 
Most normal cells as well as some integrin αvβ3 
expression-negative tumor cells such as MCF-7 breast 
tumor cells, could take up small amounts of 
Au-cRGD-DOX, resulting in low chemophotothermal 
effect from Au-cRGD-DOX [37]. Thus, the cyclic RGD 
peptide on the surface of Au NS recognizes integrin 
αvβ3 expression-positive tumor cells, and mediates 
internalization of the nanoconjugates in cells. Subse-
quent endosomal transport and lysosomal degrada-
tion could release the toxic DOX from Au-cRGD-DOX 
to induce apoptosis in cancer cell. Similarly, Xu et al. 
[38] have demonstrated the improved photothermal 
effect of combining RGD-conjugated gold nanorods 
that target integrin αvβ3 with irradiation of melanoma 
cancer cells. Xiao et al. [39] have used the gold nano-




rods conjugated with DOX and cRGD for combined 
anticancer delivery. However, to the best of our 
knowledge, we are not aware of research works com-
bining the photothermal therapeutic effect of gold 
nanostars and the chemotherapeutic effect of DOX for 
tumor-targeted therapy. The results herein demon-
strate the selective anti-tumor efficacy of 
Au-cRGD-DOX combined chemotherapy and the 
photothermal therapy under NIR laser irradiation 
could eclipse that of DOX, Au NS, or Au-DOX. 
 
 
Fig 7. A) The morphological changes of MDA-MB-231, Bel-7402 and MCF-7 tumor cells at 4 h after the treatment of four different samples (Au NS, DOX, Au NS 
+ light, Au-DOX + light, Au-cRGD-DOX + light) were compared; B) MTT assay was utilized to qualitatively display in vitro anti-tumor activity of Au NS, free DOX, 
Au-DOX and Au-cRGD-DOX on MDA-MB-231 tumor cell. Au-cRGD-DOX treated cells demonstrated the lowest cell viability (39.67 %) upon irradiated by the NIR 
light. (p < 0.05). 
 
 





Fig 8. Annexin V-FITC and PI staining were used to evaluate the cell viability following treatment of different samples. A) Morphologic changes of MDA-MB-231 and 
MCF-7 cell apoptosis after administration of the four sample (Au NS + light, DOX, Au-DOX + light, Au-cRGD-DOX + light) were compared by cell apoptosis probes 
staining and detected by confocal laser scanning microscope. Au-cRGD-DOX incubated MDA-MB-231 cells possessed the strongest red fluorescence after NIR light 
excitation. The mean red and green fluorescence intensity of B) MDA-MB-231 cells and C) MCF-7 cells after treatment of different samples were collected after 
staining of the double cell apoptosis probes. (P < 0.05). 
 
Therapy evaluation of Au-cRGD-DOX in tu-
mor-bearing mice 
Although multifunctional gold nanoparticles 
have been studied for targeted chemo- and photo-
thermal cancer treatment at cell level [40, 41], limited 
work has been done to compare their therapeutic ef-
fect in animals. Herein, the anti-tumor efficacy of 
Au-cRGD-DOX was investigated in S180 tu-
mor-bearing mice. We compared the  therapeutic ef-
fect from different administration routes (intratumor-
al or tail vein injection). Considering the limited bio-
availability of the drugs via tail vein injection, the 
intravenous dose was selected as 1.5 times as the in-
tratumoral injection dose. The images of tu-
mor-bearing mice at 9 and 18 days post-injection are 
shown in Figure S4 (Supplementary Material), after 
injecting the animals with saline, DOX, Au NS, 
Au-DOX, and Au-cRGD-DOX via intratumoral or tail 
vein injection combined with laser irradiation. Tu-
mors of the mice that received the photothermal and 
chemo-therapy from Au-cRGD-DOX via intratumoral 
or tail vein injection were similar to each other. 
However, they were obviously much smaller than 
those of other groups. In order to quantitatively ana-
lyze the therapeutic effect of samples, the survival 
rate, tumor volume, and body weight of each group of 
mice were recorded at the interval of 3 days intervals 
(Fig. 9A, Fig. 9B and Fig. 9C). The mice treated with 
Au-cRGD-DOX via intravenous injection and irradia-
tion with NIR laser maintain a 100% survival rate after 
28 days, which is higher than the mice treated with 




Au-cRGD-DOX via tail vein (87.5 %). The survival 
rate of DOX and saline treated mice were 75 % and 50 
%, respectively (Fig. 9A). As shown in Fig. 9B, tumor 
volume belonging to the mice treated with DOX, Au 
NS and Au-DOX are three to five folds larger than the 
mice treated with Au-cRGD-DOX. Furthermore, the 
tumor volume of Au-cRGD-DOX treated mice via tail 
vein injection is similar to that of Au-cRGD-DOX 
treated mice via intratumoral injection. The body 
weight of each group increased proportionately dur-
ing the observation period (Fig. 9C). The mice treated 
with saline had the lowest body weight in comparison 
with the mice in other groups. To further compare the 
anti-cancer efficiency by tail vein and intratumoral 
injection, ex vivo histology studies were performed 
(Fig. 9D). Significant necrosis occurred in the periph-
eral and central tumor region for intratumoral injec-
tion group, and only a small amount of tumor cells 
appeared around the tumor vessels. For tail vein in-
jection group, there were many cancer nests with clear 
boundary and many highly proliferating tumor cells. 
Moreover, much smaller necrotic region with patho-
logical calcification was observed in the tu-
mor-bearing mice injected by tail vein.  
 
Fig 9. Comparison of the therapeutic efficacy of Au NS + light, Au-DOX + light, free DOX, Au-cRGD-DOX+ light (intratumoral injection) and Au-cRGD-DOX + 
light (tail vein injection) in S180 tumor-bearing mice. A) Survival rates of mice in different treatment groups within 26 days; B) Tumor growth of the mice in different 
groups during treatment; C) Body weight changes of the mice in different treatment groups within 26 days; D) H&E stained tumor tissue section (periphery and 
center) of Au-cRGD-DOX treated mice at 16 days after tail vein injection or intratumoral injection. (P < 0.05). 




  Au NS has plasmon bands tunable in the NIR 
tissue optical window. These nanoparticles are very 
stable, with high potential to effectively transduce 
absorbed laser energy into heat [42]. The use of CW 
laser irradiation prevents the photo-thermal melting 
of Au Ns nanostructures into gold nano-
spheres/aggregates within seconds after exposure of 
the nanostructures to femtosecond pulse lasers [43]. 
More importantly, the surface roughness and very 
high surface-to-volume ratio of Au NS favor high 
drug loading efficiency for anti-cancer drug delivery. 
Therefore, multi-functional anti-cancer nanocon-
structs were constructed by covalently conjugating 
Au NS with targeting moiety (cRGD) and anti-cancer 
drug (DOX). A synergistic effect between the chemo-
therapy and thermotherapy was confirmed by the 
therapeutic results of Au-cRGD-DOX treated groups 
when compared with Au NS or free DOX treated 
groups. Meanwhile, the nature of targeting ligands 
can dramatically change the nanoparticle distribution 
in living subjects and the active targeting ligands did 
improve the total tumor uptake of nanoparticle, 
which was demonstrated by the different therapeutic 
results with Au-cRGD-DOX and Au-DOX. Huang et 
al. [44] suggested that the active molecular targeting 
of the tumor microenvironments does not signifi-
cantly improve the total tumor accumulation of na-
noparticles for long circulation and rigid gold nano-
particles. The work further suggested that intra-
tumoral instead of intravenous injection is the pre-
ferred route of gold nanorods administration. Ac-
cordingly, we selected a 1.5 times dose for intrave-
nous injection to compensate the loss of the drug in 
the body circulation, and tried to find out which of the 
two administration routes is a favorable one to be 
selected in tumor-targeting therapy. Our results 
showed that both routes of administration had similar 
outcomes including survival rate, tumor volume and 
body weight. Clearly, this reflects the rapid response 
of the S180 tumor model used to therapy. However, 
differences begins to emerge between the two routes 
of administration Day 25, where the intratumoral 
group retained 100% survival rate but significant de-
crease began to emerge for the intravenous group. 
Consequently, the similarity in the survival, tumor 
volume, and weight gain between the two routes of 
administration is a short-term effect that is expected to 
diverge at longer time points. The size of the particles 
is expected to influence the region of photothermal 
effect in the tumor. Intratumoral injection will deliver 
higher concentration of the multifunctional nanopar-
ticle to the tumor than intravenous injection, which 
relies on both enhanced retention and permeation as 
well as receptor mediated uptake by the tumor. Effec-
tive local concentration, therefore, depends on the 
amount of materials that reaches the target tissue, 
which is expected to be smaller for intravenous than 
intratumoral injection. Although the global response 
appeared to be similar for both routes of administra-
tions, we postulated that the local therapeutic effects 
will be different.  
Subsequently, we used histologic analysis to 
compare the anti-cancer efficiency by tail vein and 
intratumoral injection ex vivo. Tumors from intra-
tumoral injection group exhibited much larger ne-
crotic region than those from tail vein injection both in 
the peripheral or central region. This is expected be-
cause of the higher concentration of the nanoparticles 
in tumors by direct tumor injection. Extended surviv-
al studies will demonstrate the long term benefits of 
the intratumoral over intravenous administration 
route. Although our result suggests that intratumoral 
injection is a potentially effective therapeutic method, 
it is not a clinically preferred route. Therefore, efforts 
will be made to optimize the intravenous method of 
administration in future.  
Conclusion 
In summary, we have successfully developed 
tumor targeted Au-cRGD-MPA and Au-cRGD-DOX 
nanoconstructs for tumor imaging and combined 
photothermal and chemo-therapy in vivo. By taking 
advantage of NIR probe, we have directly visualized 
the biodistribution of Au-cRGD in tumor-bearing 
mice model. Tumor-targeting ability of the nanocon-
structs was dramatically enhanced in integrin 
αvβ3-overexpressing tumors by αvβ3 mediated active 
targeting. Au-cRGD-DOX was actively delivered in 
close proximity to the nucleus, and then entered the 
nucleus after longer incubation time. The tumor cells 
showed significant morphological changes and 
apoptosis upon NIR light irradiation. In comparison 
with conventional hyperthermia or chemotherapy, 
the enhanced tumor therapy efficacy was demon-
strated in Au-cRGD-DOX treated mice due to the 
combination of the dual treatment ways. Together, 
our results verified that the curative effect of the mul-
tifunctional nanoconjugates delivered by intratumoral 
injection had a decided advantage over the tail vein 
injection. The above factors provide insight into the 
development of new strategies to design drug-loaded 
nanoconstructs with increased therapeutic efficacy 
and prompt further exploration of these nanocon-
structs for combined therapy of other related diseases. 
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